{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35606520", "DateCompleted": {"Year": "2022", "Month": "05", "Day": "25"}, "DateRevised": {"Year": "2022", "Month": "07", "Day": "18"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "05", "Day": "23"}], "Language": ["eng"], "ELocationID": ["8647", "10.1038/s41598-022-11771-y"], "Journal": {"ISSN": "2045-2322", "JournalIssue": {"Volume": "12", "Issue": "1", "PubDate": {"Year": "2022", "Month": "May", "Day": "23"}}, "Title": "Scientific reports", "ISOAbbreviation": "Sci Rep"}, "ArticleTitle": "Cyanoacetohydrazide linked to 1,2,3-triazole derivatives: a new class of \u03b1-glucosidase inhibitors.", "Pagination": {"StartPage": "8647", "MedlinePgn": "8647"}, "Abstract": {"AbstractText": ["In this work, a novel series of cyanoacetohydrazide linked to 1,2,3-triazoles (9a-n) were designed and synthesized to be evaluated for their anti-\u03b1-glucosidase activity, focusing on the fact that \u03b1-glucosidase inhibitors have played a significant role in the management of type 2 diabetes mellitus. All synthesized compounds except 9a exhibited excellent inhibitory potential, with IC<sub>50</sub> values ranging from 1.00\u2009\u00b1\u20090.01 to 271.17\u2009\u00b1\u20090.30\u00a0\u03bcM when compared to the standard drug acarbose (IC<sub>50</sub>\u2009=\u2009754.1\u2009\u00b1\u20090.5\u00a0\u03bcM). The kinetic binding study indicated that the most active derivatives 9b (IC<sub>50</sub>\u2009=\u20091.50\u2009\u00b1\u20090.01\u00a0\u03bcM) and 9e (IC<sub>50</sub>\u2009=\u20091.00\u2009\u00b1\u20090.01\u00a0\u03bcM) behaved as the uncompetitive inhibitors of \u03b1-glucosidase with K<sub>i</sub>\u2009=\u20090.43 and 0.24\u00a0\u03bcM, respectively. Moreover, fluorescence measurements were conducted to show conformational changes of the enzyme after binding of the most potent inhibitor (9e). Calculation of standard enthalpy (\u0394H<sub>m</sub>\u00b0) and entropy (\u0394S<sub>m</sub>\u00b0) values confirmed the construction of hydrophobic interactions between 9e and the enzyme. Also, docking studies indicated desired interactions with important residues of the enzyme which rationalized the in vitro results."], "CopyrightInformation": "\u00a9 2022. The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran."}, {"Identifier": [], "Affiliation": "Central Research Laboratory, Shiraz University of Medical Sciences, Shiraz, Iran."}], "LastName": "Iraji", "ForeName": "Aida", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Shareghi-Brojeni", "ForeName": "Diba", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, P.O. Box 14155-6451, Tehran, 1417614411, Iran."}], "LastName": "Mojtabavi", "ForeName": "Somayeh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, P.O. Box 14155-6451, Tehran, 1417614411, Iran."}], "LastName": "Faramarzi", "ForeName": "Mohammad Ali", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Akbarzadeh", "ForeName": "Tahmineh", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran. m-saeedi@tums.ac.ir."}, {"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. m-saeedi@tums.ac.ir."}], "LastName": "Saeedi", "ForeName": "Mina", "Initials": "M"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Sci Rep", "NlmUniqueID": "101563288", "ISSNLinking": "2045-2322"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Glycoside Hydrolase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Triazoles"}, {"RegistryNumber": "EC 3.2.1.20", "NameOfSubstance": "alpha-Glucosidases"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Diabetes Mellitus, Type 2"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Glycoside Hydrolase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Kinetics"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Triazoles"}, {"QualifierName": ["metabolism"], "DescriptorName": "alpha-Glucosidases"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Nugent RA, Fathima SF, Feigl AB, Chyung D. The burden of chronic kidney disease on developing nations: A 21st century challenge in global health. Nephron Clin. Pract. 2011;118:c269\u2013c277. doi: 10.1159/000321382.", "ArticleIdList": ["10.1159/000321382", "21212690"]}, {"Citation": "Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol. 2018;14:88\u201398. doi: 10.1038/nrendo.2017.151.", "ArticleIdList": ["10.1038/nrendo.2017.151", "29219149"]}, {"Citation": "Sami W, Ansari T, Butt NS, Ab Hamid MR. Effect of diet on type 2 diabetes mellitus: A review. Int. J. Health Sci. 2017;11:65."}, {"Citation": "Das T, et al. Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy. Sci. Rep. 2021;11:1\u201315. doi: 10.1038/s41598-020-79139-8.", "ArticleIdList": ["10.1038/s41598-020-79139-8", "PMC7791137", "33414495"]}, {"Citation": "Dobric\u0103 E-C, et al. Polypharmacy in type 2 diabetes mellitus: Insights from an internal medicine department. Medicina. 2019;55:436. doi: 10.3390/medicina55080436.", "ArticleIdList": ["10.3390/medicina55080436"]}, {"Citation": "Rines AK, Sharabi K, Tavares CD, Puigserver P. Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nat. Rev. Drug Discov. 2016;15:786\u2013804. doi: 10.1038/nrd.2016.151.", "ArticleIdList": ["10.1038/nrd.2016.151", "PMC5751421", "27516169"]}, {"Citation": "Scheen AJ. Is there a role for \u03b1-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs. 2003;63:933\u2013951. doi: 10.2165/00003495-200363100-00002.", "ArticleIdList": ["10.2165/00003495-200363100-00002", "12699398"]}, {"Citation": "Moorthy NSHN, Ramos MJ, Fernandes PA. Studies on \u03b1-glucosidase inhibitors development: Magic molecules for the treatment of carbohydrate mediated diseases. Mini Rev. Med. Chem. 2012;12:713\u2013720. doi: 10.2174/138955712801264837.", "ArticleIdList": ["10.2174/138955712801264837", "22512574"]}, {"Citation": "Tseng Y-H, Tsan Y-T, Chan W-C, Sheu WH-H, Chen P-C. Use of an \u03b1-glucosidase inhibitor and the risk of colorectal cancer in patients with diabetes: A nationwide, population-based cohort study. Diabetes Care. 2015;38:2068\u20132074. doi: 10.2337/dc15-0563.", "ArticleIdList": ["10.2337/dc15-0563", "26307605"]}, {"Citation": "Hillebrand I, Boehme K, Frank G, Fink H, Berchtold P. The effects of the\u03b1-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man. Res. Exp. Med. 1979;175:81\u201386. doi: 10.1007/BF01851236.", "ArticleIdList": ["10.1007/BF01851236"]}, {"Citation": "Saeedi M, Hadjiakhondi A, Mohammad Nabavi S, Manayi A. Heterocyclic compounds: Effective \u03b1-amylase and \u03b1-glucosidase inhibitors. Curr. Top. Med. Chem. 2017;17:428\u2013440. doi: 10.2174/1568026616666160824104655.", "ArticleIdList": ["10.2174/1568026616666160824104655", "27558678"]}, {"Citation": "Saeedi M, et al. Design and synthesis of novel quinazolinone-1, 2, 3-triazole hybrids as new anti-diabetic agents: In vitro \u03b1-glucosidase inhibition, kinetic, and docking study. Bioorg. Chem. 2019;83:161\u2013169. doi: 10.1016/j.bioorg.2018.10.023.", "ArticleIdList": ["10.1016/j.bioorg.2018.10.023", "30366316"]}, {"Citation": "Saeedi M, et al. Design and synthesis of novel 5-arylisoxazole-1, 3, 4-thiadiazole hybrids as \u03b1-glucosidase inhibitors. Lett. Drug Des. Discov. 2021;18:436\u2013444. doi: 10.2174/1570180817999201104125018.", "ArticleIdList": ["10.2174/1570180817999201104125018"]}, {"Citation": "Saeedi M, et al. Synthesis of 4-alkylaminoimidazo [1, 2-a] pyridines linked to carbamate moiety as potent \u03b1-glucosidase inhibitors. Mol. Divers. 2020;25:1\u201311.", "ArticleIdList": ["32095975"]}, {"Citation": "Fattaheian-Dehkordi S, Hojjatifard R, Saeedi M, Khanavi M. A review on antidiabetic activity of Centaurea spp.: A new approach for developing herbal remedies. Evid. Based Complement. Altern. Med. 2021;2021:1\u201323. doi: 10.1155/2021/5587938.", "ArticleIdList": ["10.1155/2021/5587938"]}, {"Citation": "Shareghi-Boroujeni D, et al. Synthesis, in vitro evaluation, and molecular docking studies of novel hydrazineylideneindolinone linked to phenoxymethyl-1,2,3-triazole derivatives as potential \u03b1-glucosidase inhibitors. Bioorg. Chem. 2021;111:104869. doi: 10.1016/j.bioorg.2021.104869.", "ArticleIdList": ["10.1016/j.bioorg.2021.104869", "33839583"]}, {"Citation": "Taha M, et al. Synthesis, \u03b1-glucosidase inhibition and molecular docking study of coumarin based derivatives. Bioorg. Chem. 2018;77:586\u2013592. doi: 10.1016/j.bioorg.2018.01.033.", "ArticleIdList": ["10.1016/j.bioorg.2018.01.033", "29477126"]}, {"Citation": "Alomari M, et al. Synthesis of indole-based-thiadiazole derivatives as a potent inhibitor of \u03b1-glucosidase enzyme along with in silico study. Bioorg. Chem. 2021;108:104638. doi: 10.1016/j.bioorg.2021.104638.", "ArticleIdList": ["10.1016/j.bioorg.2021.104638", "33508679"]}, {"Citation": "Zawawi NK, et al. Benzimidazole derivatives as new \u03b1-glucosidase inhibitors and in silico studies. Bioorg. Chem. 2016;64:29\u201336. doi: 10.1016/j.bioorg.2015.11.006.", "ArticleIdList": ["10.1016/j.bioorg.2015.11.006", "26637946"]}, {"Citation": "Naureen S, et al. Biological evaluation of new imidazole derivatives tethered with indole moiety as potent \u03b1-glucosidase inhibitors. Bioorg. Chem. 2018;76:365\u2013369. doi: 10.1016/j.bioorg.2017.12.014.", "ArticleIdList": ["10.1016/j.bioorg.2017.12.014", "29232634"]}, {"Citation": "Azimi F, et al. Design, synthesis, biological evaluation, and molecular modeling studies of pyrazole-benzofuran hybrids as new \u03b1-glucosidase inhibitor. Sci. Rep. 2021;11:20776. doi: 10.1038/s41598-021-99899-1.", "ArticleIdList": ["10.1038/s41598-021-99899-1", "PMC8531348", "34675367"]}, {"Citation": "Taha M, Imran S, Rahim F, Wadood A, Khan KM. Oxindole based oxadiazole hybrid analogs: Novel \u03b1-glucosidase inhibitors. Bioorg. Chem. 2018;76:273\u2013280. doi: 10.1016/j.bioorg.2017.12.001.", "ArticleIdList": ["10.1016/j.bioorg.2017.12.001", "29223804"]}, {"Citation": "Nasli Esfahani A, et al. Design and synthesis of phenoxymethybenzoimidazole incorporating different aryl thiazole-triazole acetamide derivatives as \u03b1-glycosidase inhibitors. Mol. Divers. 2021 doi: 10.1007/s11030-021-10310-7.", "ArticleIdList": ["10.1007/s11030-021-10310-7", "PMC8436581", "34515954"]}, {"Citation": "Saeedi M, et al. Design, synthesis, in vitro, and in silico studies of novel diarylimidazole-1, 2, 3-triazole hybrids as potent \u03b1-glucosidase inhibitors. Bioorg. Med. Chem. 2019;27:115148. doi: 10.1016/j.bmc.2019.115148.", "ArticleIdList": ["10.1016/j.bmc.2019.115148", "31679980"]}, {"Citation": "Devaraj, N. K. & Finn, M. Introduction: Click Chemistry. Chem. Rev.121, 6697\u20136698 (2021)."}, {"Citation": "Kolb HC, Finn M, Sharpless KB. Click chemistry: Diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 2001;40:2004\u20132021. doi: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5.", "ArticleIdList": ["10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5"]}, {"Citation": "Saeedi M, et al. Synthesis and bio-evaluation of new multifunctional methylindolinone-1, 2, 3-triazole hybrids as anti-Alzheimer\u2032s agents. J. Mol. Struct. 2021;1229:129828. doi: 10.1016/j.molstruc.2020.129828.", "ArticleIdList": ["10.1016/j.molstruc.2020.129828"]}, {"Citation": "Askarani HK, et al. Design and synthesis of multi-target directed 1, 2, 3-triazole-dimethylaminoacryloyl-chromenone derivatives with potential use in Alzheimer\u2032s disease. BMC Chem. 2020;14:1\u201313. doi: 10.1186/s13065-019-0657-9.", "ArticleIdList": ["10.1186/s13065-019-0657-9", "PMC6945398", "31922150"]}, {"Citation": "Safavi M, et al. Novel quinazolin-4(3H)-one linked to 1,2,3-triazoles: Synthesis and anticancer activity. Chem. Biol. Drug Des. 2018;92:1373\u20131381. doi: 10.1111/cbdd.13203.", "ArticleIdList": ["10.1111/cbdd.13203", "29637699"]}, {"Citation": "Mohammadi-Khanaposhtani M, et al. Design, synthesis and cytotoxicity of novel coumarin-1, 2, 3-triazole-1, 2, 4-oxadiazole hybrids as potent anti-breast cancer agents. Lett. Drug Des. Discov. 2019;16:818\u2013824. doi: 10.2174/1570180815666180627121006.", "ArticleIdList": ["10.2174/1570180815666180627121006"]}, {"Citation": "Graciano IA, de Carvalho AS, de Carvalho da Silva F, Ferreira VF. 1, 2, 3-Triazole-and quinoline-based hybrids with potent antiplasmodial activity. Med. Chem. 2021;18:521. doi: 10.2174/1573406418666211110143041.", "ArticleIdList": ["10.2174/1573406418666211110143041"]}, {"Citation": "Alam MM. 1, 2, 3-Triazole hybrids as anticancer agents: A review. Arch. der Pharm. 2022;355:2100158. doi: 10.1002/ardp.202100158.", "ArticleIdList": ["10.1002/ardp.202100158"]}, {"Citation": "Fallah Z, et al. A review on synthesis, mechanism of action, and structure-activity relationships of 1, 2, 3-triazole-based \u03b1-glucosidase inhibitors as promising anti-diabetic agents. J. Mol. Struct. 2022;1255:132469. doi: 10.1016/j.molstruc.2022.132469.", "ArticleIdList": ["10.1016/j.molstruc.2022.132469"]}, {"Citation": "Saeedi M, et al. Synthesis and bio-evaluation of new multifunctional methylindolinone-1,2,3-triazole hybrids as anti-Alzheimer\u2032s agents. J. Mol. Struct. 2021;1229:129828. doi: 10.1016/j.molstruc.2020.129828.", "ArticleIdList": ["10.1016/j.molstruc.2020.129828"]}, {"Citation": "Yazdani M, et al. 5,6-Diphenyl triazine-thio methyl triazole hybrid as a new Alzheimer\u2019s disease modifying agents. Mol. Divers. 2020;24:641\u2013654. doi: 10.1007/s11030-019-09970-3.", "ArticleIdList": ["10.1007/s11030-019-09970-3", "31327094"]}, {"Citation": "Mahdavi M, et al. Synthesis of new benzimidazole-1,2,3-triazole hybrids as tyrosinase inhibitors. Chem. Biodivers. 2018;15:e1800120. doi: 10.1002/cbdv.201800120.", "ArticleIdList": ["10.1002/cbdv.201800120", "29766648"]}, {"Citation": "Iraji A, et al. Synthesis and structure-activity relationship study of multi-target triazine derivatives as innovative candidates for treatment of Alzheimer\u2032s disease. Bioorg. Chem. 2018;77:223\u2013235. doi: 10.1016/j.bioorg.2018.01.017.", "ArticleIdList": ["10.1016/j.bioorg.2018.01.017", "29367079"]}, {"Citation": "Asgari MS, et al. Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro \u03b1-glucosidase inhibition, kinetic, and docking studies. Bioorg. Chem. 2019;92:103206. doi: 10.1016/j.bioorg.2019.103206.", "ArticleIdList": ["10.1016/j.bioorg.2019.103206", "31445191"]}, {"Citation": "Asemanipoor N, et al. Synthesis and biological evaluation of new benzimidazole-1,2,3-triazole hybrids as potential \u03b1-glucosidase inhibitors. Bioorg. Chem. 2020;95:103482. doi: 10.1016/j.bioorg.2019.103482.", "ArticleIdList": ["10.1016/j.bioorg.2019.103482", "31838286"]}, {"Citation": "Edraki N, et al. 2-Imino 2H-chromene and 2-(phenylimino) 2H-chromene 3-aryl carboxamide derivatives as novel cytotoxic agents: Synthesis, biological assay, and molecular docking study. J. Iran. Chem. Soc. 2016;13:2163\u20132171. doi: 10.1007/s13738-016-0934-7.", "ArticleIdList": ["10.1007/s13738-016-0934-7"]}, {"Citation": "Saeedi M, et al. Novel N-benzylpiperidine derivatives of 5-arylisoxazole-3-carboxamides as anti-Alzheimer\u2032s agents. Arch. der Pharm. 2021;354:2000258. doi: 10.1002/ardp.202000258.", "ArticleIdList": ["10.1002/ardp.202000258"]}, {"Citation": "Xie Z, et al. Synthesis, biological evaluation, and molecular docking studies of novel isatin-thiazole derivatives as \u03b1-glucosidase inhibitors. Molecules. 2017;22:659. doi: 10.3390/molecules22040659.", "ArticleIdList": ["10.3390/molecules22040659"]}, {"Citation": "Jafari M, et al. Molecular level insight into stability, activity, and structure of Laccase in aqueous ionic liquid and organic solvents: An experimental and computational research. J. Mol. Liq. 2020;317:113925. doi: 10.1016/j.molliq.2020.113925.", "ArticleIdList": ["10.1016/j.molliq.2020.113925"]}, {"Citation": "Karami M, et al. One-pot multi-component synthesis of novel chromeno[4,3-b]pyrrol-3-yl derivatives as alpha-glucosidase inhibitors. Mol. Divers. 2021 doi: 10.1007/s11030-021-10337-w.", "ArticleIdList": ["10.1007/s11030-021-10337-w", "PMC8544188", "34697701"]}, {"Citation": "Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 2015;58:4066\u20134072. doi: 10.1021/acs.jmedchem.5b00104.", "ArticleIdList": ["10.1021/acs.jmedchem.5b00104", "PMC4434528", "25860834"]}, {"Citation": "Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017;7:42717. doi: 10.1038/srep42717.", "ArticleIdList": ["10.1038/srep42717", "PMC5335600", "28256516"]}, {"Citation": "Barker MK, Rose DR. Specificity of processing \u03b1-glucosidase I is guided by the substrate conformation: Crystallographic and in silico studies. J. Biol. Chem. 2013;288:13563\u201313574. doi: 10.1074/jbc.M113.460436.", "ArticleIdList": ["10.1074/jbc.M113.460436", "PMC3650392", "23536181"]}, {"Citation": "Van Der Kamp MW, et al. Dynamical origins of heat capacity changes in enzyme-catalysed reactions. Nat. Commun. 2018;9:1\u20137. doi: 10.1038/s41467-017-02088-w.", "ArticleIdList": ["10.1038/s41467-017-02088-w", "PMC5760687", "29317637"]}, {"Citation": "Farhadian S, et al. Insights into the molecular interaction between sucrose and \u03b1-chymotrypsin. Int. J. Biol. Macromol. 2018;114:950\u2013960. doi: 10.1016/j.ijbiomac.2018.03.143.", "ArticleIdList": ["10.1016/j.ijbiomac.2018.03.143", "29596937"]}, {"Citation": "Glide, V. 5.8; Schr\u00f6dinger, LLC (2012)."}, {"Citation": "Release, S. 4: Glide. Schr\u00f6dinger, LLC (2018)."}, {"Citation": "Friesner RA, et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein\u2013ligand complexes. J. Med. Chem. 2006;49:6177\u20136196. doi: 10.1021/jm051256o.", "ArticleIdList": ["10.1021/jm051256o", "17034125"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "1", "Day": "7"}, {"Year": "2022", "Month": "4", "Day": "28"}, {"Year": "2022", "Month": "5", "Day": "23", "Hour": "23", "Minute": "25"}, {"Year": "2022", "Month": "5", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "23"}], "PublicationStatus": "epublish", "ArticleIdList": ["35606520", "PMC9125976", "10.1038/s41598-022-11771-y", "10.1038/s41598-022-11771-y"]}}], "PubmedBookArticle": []}